ImmuPharma PLC (LON:IMM) continues to engage with potential corporate partners for Lupuzor, its late-stage treatment for Lupus, as well as progressing potential collaboration opportunities on its other projects.
In a brief corporate update, the AIM-listed specialist drug discovery and development company said that, following the conclusion of the pivotal Phase III trial earlier in 2018, it continues to look at opportunities which, over the longer term, have the potential of bringing Lupuzor to market.
The company noted that, together with its partner, it is in the final preparations for the Lupuzor Managed Access Program which will be open to eligible patients in Europe, with further updates to be provided to the market in due course.
It added that the Lupuzor open-label extension study, from the original Phase III trial, with a total of 62 eligible patients recruited throughout the US and Europe, remains on track to report results in the second quarter of 2019.
Nucant Cancer Programme
Turning to other areas of development, ImmuPharma said discussions are continuing on the clinical development collaboration for its Nucant Cancer Programme with - as announced on 31 December 2018 - the exclusivity period having been extended to 31 March 2019, and an update will be provided in due course.
With regards to its Bordeaux based subsidiary, Ureka SARL – which is focusing on transforming peptides into efficient drugs for treatments in a number of therapeutic areas including Type II diabetes - ImmuPharma said continues to look at all options regarding the progression of Ureka's assets.
The firm said this process is ongoing and further updates will be announced as appropriate.
Tim McCarthy, ImmuPharma's chairman said: "We remain focused on creating long term value throughout our portfolio through initiatives including the Managed Access Program for Lupuzor, whilst the Company continues to engage with industry partners for potential collaboration opportunities on its projects."